Revenue ($m): 400.8, down 12pc from year-earlier 457.0
Pre-tax profit ($m): -263.9 v year-earlier -135.4
Net profit ($m): -209.1 v year-earlier -94.5
Interim dividend: nil
Specialty pharmaceutical company Mayne Pharma Group said a weaker US dollar, COVID-19 and a tough US generics market has hurt the company, with sales and earnings down double digits in fiscal 2021.
Mayne Pharma CEO Scott Richards said growth drivers are the successful commercialisation of Nextstelllis in the US and Australia. Jesse Marlow
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
